reports
Myovant Sciences Announces Corporate Updates and Financial Results for...
Myovant Sciences Announces Corporate Updates and Financial Results for Third Fiscal Quarter 2022 Third fiscal quarter 2022 total revenue of $100.2 million; including net product revenue of $61.4 millionNet product revenue from U.S. sales of ORGOVYX® of $48.7 million in third fiscal quarter 2022, with sequential quarterly demand volume growth of 13% and cumulative patients estimated at 26,000 through December 2022Net product revenue from U.S. sales of MYFEMBREE® of $10.5 million in third fiscal quarter 2022, with sequential quarterly demand volume growth of 49% and cumulative patients estima...
Myovant Sciences Announces New Employment Inducement Grants Under NYSE...
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08 BASEL, Switzerland, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, today announced that it approved equity awards for 18 new employees with a grant date of November 15, 2022 pursuant to Myovant’s 2020 Inducement Plan. The equity awards were granted to the employees joining Myovant in accordance with NYSE’s Listed Company Manual ...
Myovant Sciences Appoints Ann Tomlin as Senior Vice President of Human...
Myovant Sciences Appoints Ann Tomlin as Senior Vice President of Human Resources BASEL, Switzerland, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) today announced the appointment of Ann Tomlin as Senior Vice President of Human Resources. Beginning November 28, Ms. Tomlin will be responsible for developing talent solutions and human resources strategies across Myovant’s global functions. She will serve as a member of the Executive Committee and will report to David Marek, Myovant’s Chief Executive Officer. Ms. Tomlin has over 25 years of human resources experience with a...
Myovant Sciences Announces Corporate Updates and Financial Results for...
Myovant Sciences Announces Corporate Updates and Financial Results for Second Fiscal Quarter 2022 On October 23, 2022, Sumitovant Biopharma Ltd. (Sumitovant), in conjunction with parent company Sumitomo Pharma Co., Ltd. (Sumitomo Pharma), and Myovant Sciences (Myovant) announced that they have entered into a definitive agreement pursuant to which Sumitovant will acquire all outstanding shares of Myovant not already owned by Sumitovant for $27.00 per share in cash. This corresponds to a total transaction value of $1.7 billion on a fully diluted basis, and a total company value of $2.9 billio...
Myovant Sciences Cancels Second Quarter Earnings Conference Call
Myovant Sciences Cancels Second Quarter Earnings Conference Call BASEL, Switzerland, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) (“Myovant”) today announced the cancellation of its earnings conference call for the quarter ended September 30, 2022 that had originally been scheduled for October 26, 2022 at 5:00 p.m. Eastern Time. The call is being cancelled due to the announcement of the pending merger with Sumitovant Biopharma Ltd. ABOUT MYOVANT SCIENCES Myovant Sciences aspires to redefine care for women and men through purpose-driven science, empowering medicines, a...
Sumitovant Biopharma, Sumitomo Pharma, and Myovant Sciences Enter into...
Sumitovant Biopharma, Sumitomo Pharma, and Myovant Sciences Enter into Definitive Agreement Sumitovant Biopharma to Acquire all Outstanding Shares of Myovant for $27 Per Share in Cash Combination Provides Expertise and Resources to Address Unmet Patient Needs in Women’s Health and Prostate Cancer Agreement Unanimously Recommended by Special Committee of Myovant’s Independent Directors and Approved by Board NEW YORK and BASEL, Switzerland and OSAKA, Japan, Oct. 23, 2022 (GLOBE NEWSWIRE) -- Sumitovant Biopharma Ltd. (“Sumitovant”), in conjunction with parent company Sumitomo Pharma Co.,...
Myovant Sciences Announces New Employment Inducement Grants Under NYSE...
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08 BASEL, Switzerland, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, today announced that it approved equity awards for 10 new employees with a grant date of October 17, 2022 pursuant to Myovant’s 2020 Inducement Plan. The equity awards were granted to the employees joining Myovant in accordance with NYSE’s Listed Company Manual R...
CORRECTION -- Myovant Sciences, Inc.
CORRECTION -- Myovant Sciences, Inc. BASEL, Switzerland, Oct. 14, 2022 (GLOBE NEWSWIRE) -- In a release issued under the headline "Myovant Sciences to Host Second Fiscal Quarter 2022 Earnings Conference Call at 5:00 p.m." earlier today by Myovant Sciences, Inc. (NYSE: MYOV), please note that the date of the conference call was omitted from the headline. The corrected release follows: Myovant Sciences to Host Second Fiscal Quarter 2022 Earnings Conference Call at 5:00 p.m. Eastern Time on October 26, 2022 Myovant Sciences (NYSE: MYOV), today announced it will host a webcast and conferenc...
Myovant Sciences to Host Second Fiscal Quarter 2022 Earnings Conferenc...
Myovant Sciences to Host Second Fiscal Quarter 2022 Earnings Conference Call at 5:00 p.m. BASEL, Switzerland, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), today announced it will host a webcast and conference call to discuss corporate updates and financial results for its second fiscal quarter, ended September 30, 2022. The webcast and conference call will be held at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on October 26, 2022. Investors and the general public may access the live webcast . The live webcast can also be accessed by visiting the company’s invest...
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
Another Bear Market Rally Brewing? In last week's Compass (Sept. 27) we discussed our belief that the market indexes could see a bounce or pause in selling, citing numerous oversold indexes/Sectors that were testing critical supports, including 3636 on the S&P 500, $269 on the Nasdaq 100 (QQQ), and $162 on the Russell 2000 (IWM). Sector and index supports held, and early indications suggest a bear market rally is brewing, and potentially that the lows are in for this bear market, helped by shor...
EME EMCOR GROUP
XENE XENON PHARMACEUTICALS INC
SAGE SAGE THERAPEUTICS INC.
RVNC REVANCE THERAPEUTICS INC.
PTCT PTC THERAPEUTICS INC.
MCRB SERES THERAPEUTICS
GERN GERON CORP.
DY DYCOM INDUSTRIES INC.
AGIO AGIOS PHARMACEUTICALS INC.
ADMA ADMA BIOLOGICS INC
SNDX SYNDAX PHARMACEUTICALS
MYOV MYOVANT SCIENCE
KNSA KINIKSA PHARMACEUTICALS
AKRO AKERO THERAPEUTICS
PWR CAPTIVA VERDE WELLNESS CORP.
Myovant Sciences Special Committee of Board Confirms Receipt of Prelim...
Myovant Sciences Special Committee of Board Confirms Receipt of Preliminary, Non-binding Proposal from Sumitovant Biopharma and Sumitomo Pharma to Acquire Remaining Shares BASEL, Switzerland, Oct. 02, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences Ltd. (NYSE: MYOV) (the “Company”) confirmed today that it has received a preliminary, non-binding proposal (the “Proposal”) from Sumitovant Biopharma Ltd. (“Sumitovant”) and Sumitomo Pharma Co., Ltd. (collectively with Sumitovant, “Sumitomo”) to acquire the remaining shares of the Company that Sumitovant does not currently hold, for a price of $22.75...
Myovant Sciences Announces New Employment Inducement Grants Under NYSE...
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08 BASEL, Switzerland, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, today announced that it approved equity awards for 7 new employees with a grant date of September 15, 2022 pursuant to Myovant’s 2020 Inducement Plan. The equity awards were granted to the employees joining Myovant in accordance with NYSE’s Listed Company Manual...
Myovant Recognizes Prostate Cancer Awareness Month with Educational Sp...
Myovant Recognizes Prostate Cancer Awareness Month with Educational Sponsorships and Online Campaign to Encourage Patients to Speak Up, Seek Support and Be Informed Peer Video Series Campaign and Educational Sponsorships Spotlight Patient Barriers to Conversations BASEL, Switzerland, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) today announced an educational campaign to inspire prostate cancer patients to speak up and seek support through authentic conversations, along with the sponsorship of educational opportunities for patients, providers, and caregivers during Pr...
Myovant Sciences to Participate at Upcoming Investor Conferences
Myovant Sciences to Participate at Upcoming Investor Conferences BASEL, Switzerland, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, today announced that David Marek, Chief Executive Officer of Myovant Sciences, Inc., and Uneek Mehra, Chief Financial and Business Officer, will participate in the following upcoming investor conferences: Citi's 17th Annual BioPharma Conference on Thursday, September 8, 2022. Man...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
HURN HURON CONSULTING GROUP INC.
ESPR ESPERION THERAPEUTICS INC.
CNCE CONCERT PHARMACEUTICALS
A AGILENT TECHNOLOGIES INC.
ARCLK ARCELIK A.S.
CCRN CROSS COUNTRY HEALTHCARE INC.
SJT SAN JUAN BASIN ROYALTY TRUST
MYOV MYOVANT SCIENCE
MRSN MERSANA THERAPEUTICS
VERU VERU
HHS HARTE-HANKS INC.
COGT COGENT BIOSCIENCES INC
JAKK JAKKS PACIFIC INC.
HOWL WEREWOLF THERAPEUTICS INC
LYEL LYELL IMMUNOPHARMA INC
Myovant Sciences Announces New Employment Inducement Grants Under NYSE...
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08 BASEL, Switzerland, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, today announced that it approved equity awards for 11 new employees with a grant date of August 15, 2022 pursuant to Myovant’s 2020 Inducement Plan. The equity awards were granted to the employees joining Myovant in accordance with NYSE’s Listed Company Manual Ru...
Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE®, a...
Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE®, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis Data from the Phase 3 SPIRIT program showed MYFEMBREE reduced menstrual pain and non-menstrual pelvic pain in premenopausal women with endometriosis, and a loss of mean bone mineral density of less than 1% from baseline through one year of treatment Myovant and Pfizer will continue to jointly commercialize MYFEMBREE, with product available immediatelyMyovant to host conference call and webcast on Monday, August 8, 2022, at 8:...
Myovant Sciences Announces Corporate Updates and Financial Results for...
Myovant Sciences Announces Corporate Updates and Financial Results for First Fiscal Quarter 2022 First fiscal quarter 2022 total revenue of $116.5 million, including net product revenue of $41.4 million Net product revenue from U.S. sales of ORGOVYX® of $36.0 million in first fiscal quarter 2022, with sequential quarterly demand volume growth of 26% and cumulative patients estimated at 18,000 through June 2022Net product revenue from U.S. sales of MYFEMBREE® of $4.0 million in first fiscal quarter 2022, with sequential quarterly demand volume growth of 54%MYFEMBREE remains the number one p...
Myovant Sciences Announces New Employment Inducement Grants Under NYSE...
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08 BASEL, Switzerland, July 18, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, today announced that it approved equity awards for 9 new employees with a grant date of July 15, 2022 pursuant to Myovant’s 2020 Inducement Plan. The equity awards were granted to the employees joining Myovant in accordance with NYSE’s Listed Company Manual Rule ...
Myovant Sciences to Host First Fiscal Quarter 2022 Earnings Conference...
Myovant Sciences to Host First Fiscal Quarter 2022 Earnings Conference Call at 5:00 p.m. Eastern Time on July 27, 2022 BASEL, Switzerland, July 13, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), today announced it will host a webcast and conference call to discuss corporate updates and financial results for its first fiscal quarter, ended June 30, 2022. The webcast and conference call will be held at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on July 27, 2022. Investors and the general public may access the live webcast . The live webcast can also be accessed by visitin...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.